Safety, Efficacy and Persistence of Advanced Therapies in Inflammatory Bowel Disease: Results from ORIGINS. A Retrospective Observational Study
Journal of Gastrointestinal and Liver Diseases · 2023
DOI: 10.15403/jgld-5128 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of Gastrointestinal and Liver Diseases, 2023. Verfasst von Radu Bogdan Mateescu und 25 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology Department, Colentina Clinical Hospital, Bucharest, Romania. . bogmateescu@gmail.com. Hauptthemen laut MEDLINE: Inflammatory Bowel Diseases, Colitis, Ulcerative, Biological Products. Die Arbeit wurde bisher 6-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background and Aims: Real-world assessments of efficacy and safety of advanced therapies used for inflammatory bowel disease (IBD) patients are limited. We aimed to report safety, efficacy and treatment persistence of new molecules (infliximab, adalimumab, vedolizumab, tofacitinib, ustekinumab) in a retrospective multicentric national Romanian analysis.
Methods
We conducted a nationwide, retrospective observational multicentric study. Data were collected retrospectively from electronic and paper files. Patients who started on one of the five investigated molecules during December 2019-December 2021 were included. The main outcome measures were clinical remission, endoscopic healing, persistence on treatment and safety data.
Results
A total of 678 adult patients from 24 Romanian IBD centers with a diagnosis of ulcerative colitis or Crohn’s disease were included. Participants had previously failure to one (268, 39.5%), two (108, 15%) or more treatment lines and only 38% (259) were biologic naïve. In the 24 months study period, most patients were started on vedolizumab (192, 28%), followed by adalimumab, infliximab, ustekinumab and tofacitinib. In biologic-naïve patients, most physicians (72%) preferred anti-TNF treatment as first line biologic (93 patients started on infliximab, 92 on adalimumab), followed by vedolizumab, ustekinumab and tofacitinib. During follow-up, 71% (470, p=0.05) of patients achieved clinical remission and 36% (134, p=0.03) achieved mucosal healing. The 6 months milestone for persistence was reached in 78% (530) of cases. Almost half of patients (47%, 316 patients) persisted on their current treatment for over 12 months. Overall, an adverse reaction was reported for 67 (10.4%) patients, with no lethal events.
Conclusions
Population of biologic-experienced IBD patients in Romania is increasing and is becoming more difficult to achieve long-term disease control. Discontinuation rates for advanced therapies are high.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Gastroenterology Department, Colentina Clinical Hospital, Bucharest, Romania. . bogmateescu@gmail.com.
- Gastroenterology and Hepatology Center, Fundeni Clinical Institute,Bucharest, Romania. drcgheorghe@gmail.com.
- Gastroenterology Department, St. Spiridon Emergency Clinical County Hospital, Iasi, Romania. ancatrifan@yahoo.com.
- Gastroenterology Department, Elias Emergency Hospital, Bucharest, Romania. adriansaftoiu@gmail.com.
- Gastroenterology Department, Prof. Dr. Octavian Fodor Gastroenterology Institute, Cluj-Napoca, Romania. andradaseicean@gmail.com.
- Gastroenterology and Hepatology Center, Fundeni Clinical Institute,Bucharest, Romania. mmdiculescu@yahoo.com.
Zitieren
APA
Mateescu, R. B., Gheorghe, C., Trifan, A. V., Saftoiu, A., Seicean, A., Diculescu, M. M., Banciu, C., Gheorghe, L. S., Busuioc, B., Goldis, A., Dobru, D., Fratila, O., Eugen, D., Bataga, S., Constantinescu, G., Gheonea, D., Tantau, A., Jinga, M., Brisc, C., …, & Negreanu, L. (2023). Safety, Efficacy and Persistence of Advanced Therapies in Inflammatory Bowel Disease: Results from ORIGINS. A Retrospective Observational Study. Journal of Gastrointestinal and Liver Diseases. https://doi.org/10.15403/jgld-5128
Vancouver
Mateescu RB, Gheorghe C, Trifan AV, Saftoiu A, Seicean A, Diculescu MM, et al. Safety, Efficacy and Persistence of Advanced Therapies in Inflammatory Bowel Disease: Results from ORIGINS. A Retrospective Observational Study. Journal of Gastrointestinal and Liver Diseases. 2023. doi:10.15403/jgld-5128
BibTeX
@article{Mateescu2023,
author = {Mateescu, Radu Bogdan and Gheorghe, Cristian and Trifan, Anca Victorita and Saftoiu, Adrian and Seicean, Andrada and Diculescu, Mihai Mircea and Banciu, Christian and Gheorghe, Liliana Simona and Busuioc, Bogdan and Goldis, Adrian and Dobru, Daniela and Fratila, Ovidiu and Eugen, Dumitru and Bataga, Simona and Constantinescu, Gabriel and Gheonea, Dan and Tantau, Alina and Jinga, Mariana and Brisc, Ciprian and Cijevschi Prelipcean, Cristina and Chira, Romeo and Fierbințeanu-Braticevici, Carmen and Dumitrascu, Dan and State, Monica and Voiosu, Theodor and Negreanu, Lucian},
title = {Safety, Efficacy and Persistence of Advanced Therapies in Inflammatory Bowel Disease: Results from ORIGINS. A Retrospective Observational Study},
journal = {Journal of Gastrointestinal and Liver Diseases},
year = {2023},
doi = {10.15403/jgld-5128}
}
EUVIMED